Roche gambled on an all-comer design for trials of its COPD candidate astegolimab, a move that may prove costly as it fails a phase 3 test.

Novartis hopes of bringing Cosentyx to patients with giant cell arteritis seem to be over after the drug missed all the endpoints in a phase 3 trial.